Andrew Yates at Think Gene has a post about direct-to-consumer genomic testing and why programs like the Coriell Institute's Personalized Medicine Collaborative (free to patients) might be taking some of the wind out of corporate sails. "The problem is that DTC genomic companies aren't profitable," Yates writes. With one organization offering to do testing for free, it'll be tougher to convince investors that there's a good chance for return on investment, he says.